Compare Crocs, Inc. (CROX) vs TransMedics Group Inc (TMDX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Crocs, Inc. vs TransMedics Group Inc — how do they compare? Crocs, Inc. trades at $116.68 (market cap $5.60B), while TransMedics Group Inc trades at $79.01 (market cap $2.74B). The key difference: Crocs, Inc. is far larger — about 2× TransMedics Group Inc's market cap, and Crocs, Inc. is trading nearer its 52-week high, TransMedics Group Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Crocs, Inc. for 96 Days and TransMedics Group Inc for 24 Days on average.
| CROX | TMDX | |
|---|---|---|
Market Cap | $5.60B | $2.74B |
Volume | 1,026,773 | 949,331 |
Sector | Consumer Cyclical | Health |
52-Week High | $141.19 | $150.42 |
52-Week Low | $73.39 | $61.99 |
Typical Hold Time | 96 Days | 24 Days |
Enterprise Value | $7.12B | $3.13B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CROX trades at $115.20, down 4.18% amid bearish technical signals, though valuation metrics appear attractive with a P/E of 10.23 and P/S of 1.46. Recent earnings beats and a 51% analyst buy rating support fundamental strength, but 2025 net income turned negative due to tax impacts. The stock faces resistance near $116-119 with support at $114.
Outlook remains mixed: strong brand positioning and earnings momentum contrast with technical weakness and recent profitability challenges. The consensus price target of $136.78 suggests 19% upside, but investors should weigh competitive pressures and consumer spending volatility against valuation appeal.
TMDX trades at $81.07, up 0.98% today, but faces a bearish technical signal with recent price weakness. Fundamentally, the company reported strong 2025 results with $605.49M revenue and $190.29M net income, though 2026 projections show margin compression. Recent news highlights insider buying and ongoing legal investigations into fiduciary duties, creating mixed sentiment.
The stock offers potential upside to the $99.75 consensus target, supported by a 69% buy rating from analysts, but risks include earnings misses, margin pressure from heavy investment, and legal overhangs. Execution on growth amid rising costs remains critical for sustaining its premium valuation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Crocs, Inc.
Crocs Inc is engaged in the design, development, marketing, distribution, and sale of casual lifestyle footwear accessories for men, women, and children. The reportable geographic segments of the company include Americas, Asia pacific, and EMEA.
Read more on CROX →About TransMedics Group Inc
TransMedics is a pioneering medical technology company that is disrupting the organ transplant market with its Organ Care System (OCS™). By replacing traditional cold storage with portable warm perfusion, the OCS maintains donor organs in a near-physiologic state, allowing for continuous assessment and optimization. Through its National OCS Program (NOP™), TransMedics provides an end-to-end clinical and logistics solution, including a dedicated aviation fleet, to maximize the utilization of donor organs and improve patient outcomes.
Read more on TMDX →
